IL23A and acquired polycythemia vera: Ustekinumab (Stelara®) is a human IgG1κ monoclonal antibody against the p40 subunit of the IL12 and IL23 cytokines that has demonstrated significant improvement in outcome measures for the treatment of PV in Phase III clinical trials [100].